Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016
Intrinsic Value
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, production, and sale of aortic and peripheral vascular interventional medical devices. [ Read More ]
The intrinsic value of one
Shanghai MicroPort Endovascular MedTech Group Co Ltd
stock under the Base Case scenario is
169.84
CNY.
Compared to the current market price of 121.5 CNY,
Shanghai MicroPort Endovascular MedTech Group Co Ltd
is
Undervalued by 28%.
Shanghai MicroPort Endovascular MedTech Group Co Ltd's market capitalization is 15B CNY.
Shanghai MicroPort Endovascular MedTech Group Co Ltd stock price is 121.5 CNY.
Shanghai MicroPort Endovascular MedTech Group Co Ltd stock price (121.5 CNY) is 28% less than its Intrinsic Value (169.84 CNY).
Shanghai MicroPort Endovascular MedTech Group Co Ltd stock price (121.5 CNY) is 31% less than its DCF Value (176.14 CNY). Open DCF Valuation
Shanghai MicroPort Endovascular MedTech Group Co Ltd stock price (121.5 CNY) is 26% less than its Relative Value (163.53 CNY). Open Relative Valuation
Shanghai MicroPort Endovascular MedTech Group Co Ltd has upside potential of 99% compared to the average analyst price target.
Open Wall St Estimates
Shanghai MicroPort Endovascular MedTech Group Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 21% to 19%.
Shanghai MicroPort Endovascular MedTech Group Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 19%.
Shanghai MicroPort Endovascular MedTech Group Co Ltd's Revenue has grown by an exceptional 36% over the past 12 months.
Shanghai MicroPort Endovascular MedTech Group Co Ltd's Revenue is forecast to grow at a rate of 29% per year over the next 3 years.
Shanghai MicroPort Endovascular MedTech Group Co Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 77% to 45%.
Shanghai MicroPort Endovascular MedTech Group Co Ltd has positive three-year average ROE (Return on Equity): 22%. The company is efficient at transforming stockholders' equity into net income.
Shanghai MicroPort Endovascular MedTech Group Co Ltd's Revenue has been growing by an exceptional 30% per year for the last 3 years.
Shanghai MicroPort Endovascular MedTech Group Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 45%.
Shanghai MicroPort Endovascular MedTech Group Co Ltd has positive Operating Income for the last twelve months.
Shanghai MicroPort Endovascular MedTech Group Co Ltd has positive Net Income for the last twelve months.
Shanghai MicroPort Endovascular MedTech Group Co Ltd has positive Gross Profit for the last twelve months.
Shanghai MicroPort Endovascular MedTech Group Co Ltd has positive Free Cash Flow for the last twelve months.
Shanghai MicroPort Endovascular MedTech Group Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.01.
Shanghai MicroPort Endovascular MedTech Group Co Ltd has very high three-year average ROIC (Return on Invested Capital): 58%. The company is very efficient at using invested capital to generate operating income.
Shanghai MicroPort Endovascular MedTech Group Co Ltd's short-term assets (4B CNY) exceed its short-term liabilties (361m CNY).
Shanghai MicroPort Endovascular MedTech Group Co Ltd's long-term assets (5B CNY) exceed its long-term liabilties (482m CNY).
Shanghai MicroPort Endovascular MedTech Group Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (3B CNY) than debt (21m CNY).
Shanghai MicroPort Endovascular MedTech Group Co Ltd's Altman Z-Score is very high and is equal to 20.1.
Valuation Backtest
Shanghai MicroPort Endovascular MedTech Group Co Ltd
Run backtest to discover the historical profit from buying and selling
Shanghai MicroPort Endovascular MedTech Group Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Shanghai MicroPort Endovascular MedTech Group Co Ltd
Balance Sheet Decomposition
Shanghai MicroPort Endovascular MedTech Group Co Ltd
| Current Assets | 3.6B |
| Cash & Short-Term Investments | 3.2B |
| Receivables | 194.8m |
| Other Current Assets | 252.3m |
| Non-Current Assets | 899.1m |
| Long-Term Investments | 123m |
| PP&E | 334.6m |
| Intangibles | 366.5m |
| Other Non-Current Assets | 75.1m |
| Current Liabilities | 360.5m |
| Accounts Payable | 42.7m |
| Accrued Liabilities | 60.6m |
| Other Current Liabilities | 257.2m |
| Non-Current Liabilities | 121.3m |
| Long-Term Debt | 21.3m |
| Other Non-Current Liabilities | 100m |
Earnings Waterfall
Shanghai MicroPort Endovascular MedTech Group Co Ltd
|
Revenue
|
1.3B
CNY
|
|
Cost of Revenue
|
-307.3m
CNY
|
|
Gross Profit
|
952.4m
CNY
|
|
Operating Expenses
|
-330.8m
CNY
|
|
Operating Income
|
621.6m
CNY
|
|
Other Expenses
|
-69.8m
CNY
|
|
Net Income
|
551.9m
CNY
|
Free Cash Flow Analysis
Shanghai MicroPort Endovascular MedTech Group Co Ltd
Profitability Score
Profitability Due Diligence
Shanghai MicroPort Endovascular MedTech Group Co Ltd's profitability score is 79/100. The higher the profitability score, the more profitable the company is.
Score
Shanghai MicroPort Endovascular MedTech Group Co Ltd's profitability score is 79/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Shanghai MicroPort Endovascular MedTech Group Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Shanghai MicroPort Endovascular MedTech Group Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Shanghai MicroPort Endovascular MedTech Group Co Ltd
According to Wall Street analysts, the average 1-year price target for
Shanghai MicroPort Endovascular MedTech Group Co Ltd
is 241.77 CNY
with a low forecast of 232.3 CNY and a high forecast of 264.74 CNY.
Shareholder Return
Price
Shanghai MicroPort Endovascular MedTech Group Co Ltd
| Average Annual Return | 10.3% |
| Standard Deviation of Annual Returns | 40.69% |
| Max Drawdown | -73% |
| Market Capitalization | 15B CNY |
| Shares Outstanding | 123 262 116 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Shanghai MicroPort Endovascular MedTech Group Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, production, and sale of aortic and peripheral vascular interventional medical devices. The company is headquartered in Shanghai, Shanghai and currently employs 660 full-time employees. The company went IPO on 2019-07-22. The firm's main products include the aortic stent graft system for aortic minimally invasive interventional procedures, the intraoperative stent system for open surgery, as well as the peripheral vascular stent system and peripheral balloon dilatation catheters for the treatment of peripheral vascular diseases. The firm mainly distributes its products to the domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one
Shanghai MicroPort Endovascular MedTech Group Co Ltd
stock under the Base Case scenario is
169.84
CNY.
Compared to the current market price of 121.5 CNY,
Shanghai MicroPort Endovascular MedTech Group Co Ltd
is
Undervalued by 28%.
You don't have any saved screeners yet
